Follicular lymphoma

Indication for Interferon, alfa-2b

Population group: Suitable for both men and women, only adults (18 - 65 years old)

For this indication, competent medicine agencies globally authorize below treatments:

5 million IU once every other day

Route of admnistration

Subcutaneous

Defined daily dose

5,000,000 - 5,000,000 [iU]

Dosage regimen

From 5,000,000 To 5,000,000 [iU] once every 2 day(s)

Detailed description

Adjunctively with chemotherapy, interferon alfa-2b may be administered subcutaneously, at a dose of 5 million IU three times a week (every other day) for a duration of 18 months. CHOP-like regimens are advised, but clinical experience is available only with CHVP (combination of cyclophosphamide, doxorubicin, teniposide and prednisolone).

Active ingredient

Recombinant interferon alfa-2b is a sterile, stable, formulation of highly purified interferon alfa-2b produced by recombinant DNA techniques. Interferons exert their cellular activities by binding to specific membrane receptors on the cell surface. Recombinant interferon alfa-2b has exhibited antiproliferative effects in studies employing both animal and human cell culture systems as well as human tumour xenografts in animals. It has demonstrated significant immunomodulatory activity in vitro.

Read more about Interferon, alfa-2b

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner